Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Higher Catastrophic Costs, Drug Price Trends Push Part D Rates Up $3 In 2009

Executive Summary

Medicare drug plans are continuing to refine their premium calculations to reflect actual program experience, including sometimes higher-than-expected costs, a snapshot of 2009 bid submissions suggests. For example, CMS says that higher spending for individuals who reach the catastrophic cost ceiling is one factor in the $3 increase in the Medicare benchmark premium for 2009

You may also be interested in...



UnitedHealth Clipped By SNPs: Medicare Chronic Care Plans Too Costly

UnitedHealth Group has stopped marketing its Medicare Advantage chronic special needs plans in major markets in an effort to stem losses from much higher than expected costs this year

Humana Reviewing Extent Of Part D Brand Coverage To Cut Costs In 2009

National Part D sponsor Humana has run into financial trouble again with its stand-alone Medicare drug plans

FDA 2015 Budget Increase Proposal Leans On Food Safety User Fees

Food safety programs would get the largest increase in the White House’s proposed fiscal 2015 FDA budget, and increases in user fee programs are proposed as key drivers for the boost. The agency’s overall budget would grow $335 million to $4.7 billion in the proposal.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS049995

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel